New Trial Data: ST-920 Gene Therapy Effective, Well-tolerated in Fabry
Gene therapy ST-920 (isaralgagene civaparvovec) continues to be effective and well-tolerated in adults with Fabry disease, according to the latest data from an ongoing Phase 1/2 clinical trial that’s testing the experimental treatment. Five of the participants treated with ST-920 the longest — up to 15 months, or…